Innovent Reports $46 Million of Revenue for its PD-1 in 2019 First Half

Innovent Bio of Suzhou announced financial results for its first six months results as a commercial entity: the company launched Tyvyt®, its PD-1 checkpoint inhibitor on March 9. During the nearly four months of active sales, Tyvyt produced revenues of $46 million, nearly all of Innovent's revenues. Tyvyt is approved as a third-line treatment for classical Hodgkin's lymphoma, though Innovent is conducting 20 trials of Tyvyt, its first commercial product, eight of them pivotal. Innovent priced Tyvyt at $1,097 per vial, a 60% discount to Merck's PD-1, Keytruda. More details....

Stock Symbols: (HK: 01801) (NYSE: MRK)

Share this with colleagues: